German chemical and pharma group Merck KGaA has acknowledged that it is in talks to buy US biotech SpringWorks, but cautioned there is no guarantee a deal will be forthcoming. Merck said in a ...

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks about a possible takeover, a new FDA approval could have sweetened the deal. Stamford, Connecticut-based SpringWorks ...

Barclays maintained an 'Overweight' rating on SpringWorks, with a price target of $63. It sees limited regulatory risk to a potential Merck buyout. Retail traders on Stocktwits reacted strongly to ...

BofA lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $84 from $87 and keeps a Buy rating on the shares. While Q1 ...

February 11, 2025 Germany's Merck in advanced talks to acquire US biotech firm SpringWorks Merck KGaA , the German healthcare and technology group, said on Monday it is in advanced talks to ...

One of the most significant developments for SpringWorks is the ongoing merger and acquisition discussions with Merck KGaA. Analysts view this potential acquisition as strategically sound for several ...

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Springworks Therapeutics (SWTX – Research Report) today and set a ...